08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Design Assistant in Planegg kostenlos abonnieren.